Atellica IM Prostate-Specific Antigen (PSA)
FDA premarket approval P950021/S015 · decided 2018-08-03
Approval details
- PMA number
- P950021
- Supplement
- S015
- Supplement type
- Normal 180 Day Track
- Supplement reason
- Change Design/Components/Specifications/Material
- Trade name
- Atellica IM Prostate-Specific Antigen (PSA)
- Generic name
- Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer
- Applicant
- Siemens Healthcare Diagnostics
- Date received
- 2017-08-01
- Decision date
- 2018-08-03
- Days to decision
- 367 days
- Decision code
- APPR
- Product code
- MTF
- Advisory committee
- Immunology
- Expedited review
- No
- Location
- East Walpole, MA
- Statement
- Approval of the migration of the ADVIA Centaur PSA Assay to the Atellica IM Analyzer.
Class III intelligence, same tools
PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.